Cellyan Biotechnology Co., Ltd has been addressing Nasdaq compliance issues related to its minimum bid price, receiving extensions to regain compliance. Financial disclosures indicate modest revenue and net income with liquidity ratios reflecting a strong current ratio but low cash ratio.

• On January 16, 2026, Cellyan received a Nasdaq notice for failing to maintain the minimum bid price of $1.00 per share for 30 consecutive business days, initiating a 180-day compliance period [N2].
• On July 14, 2026, Nasdaq granted Cellyan an additional 180-day extension to regain compliance with the minimum bid price requirement [N1].
• As of September 30, 2025, the company reported revenue of $7.1 million and net income of $153,735 for the six months ended on that date [S2].
• Liquidity ratios as of September 30, 2025, include a current ratio of 2.93 and a cash ratio of 0.06, with cash and cash equivalents totaling $190,912 [S2].

The company has demonstrated the ability to generate revenue and net income within its reported period and maintains liquidity above current liabilities. It has secured extensions from Nasdaq to address compliance issues, indicating ongoing engagement with regulatory requirements. Its cybersecurity and governance frameworks are established and overseen by senior management and the board.

The company is currently non-compliant with Nasdaq’s minimum bid price requirement, which poses a risk to its listing status. Limited public disclosure on its business model, industry specifics, and growth strategy reduces transparency. The low cash ratio suggests limited immediate cash liquidity relative to current liabilities, which may constrain operational flexibility.

The company’s moat is not explicitly detailed in public disclosures. It operates in biotechnology, a sector typically characterized by intellectual property and regulatory barriers, but specific competitive advantages or proprietary technologies are not described in available filings or news.

• Nasdaq Listing Compliance Risk: The company has received notices for failing to maintain the minimum bid price of $1.00 per share and has been granted extensions to regain compliance, posing a risk to its continued Nasdaq listing [N2][N1].
• Liquidity Risk: While the current ratio is strong at 2.93, the cash ratio is low at 0.06 as of September 30, 2025, indicating limited cash on hand relative to current liabilities [S2].
• Limited Business Model Disclosure: Public disclosures lack detailed information on the company’s specific biotechnology products, markets, and competitive positioning, limiting visibility into its operational risks and opportunities [S1].
• Foreign Currency and Interest Rate Risks: The company is exposed to foreign currency risk primarily through US dollar transactions and interest rate risk related to bank borrowings and deposits, though these risks are currently considered minimal [S1].

• Cellyan Biotechnology Co., Ltd is a foreign private issuer incorporated in the Cayman Islands with principal executive offices in Hong Kong [S1].
• The company completed its initial public offering (IPO) on January 16, 2025, issuing 1,403,685 ordinary shares at $4.00 per share, generating gross proceeds of approximately $5.6 million before expenses [S1].
• As of September 30, 2025, the company reported revenue of $7,137,140 and net income of $153,735 for the six months ended on that date [S2].
• Basic and diluted earnings per share were $0.014 as of September 30, 2025 [S2].
• Liquidity ratios as of September 30, 2025, include a current ratio of 2.93 and a cash ratio of 0.06, with cash and cash equivalents totaling $190,912 [S2].
• The company is exposed to foreign currency risk primarily through US dollar-denominated service income and expenses, with minimal exchange rate risk due to the Hong Kong dollar peg to the US dollar [S1].
• Interest rate risk relates to bank borrowings and interest income from cash deposits; the company has not used derivatives to manage this risk [S1].
• Inflation impact is considered not material, with Hong Kong inflation rates stable around 1.4% to 2% in recent years [S1].
• The company maintains a technology and cybersecurity program with preventive measures, training, and crisis management procedures overseen by senior management and the board of directors [S1].
• Cellyan Biotechnology Co., Ltd received a Nasdaq notice on January 16, 2026, for failing to maintain the minimum bid price of $1.00 per share for 30 consecutive business days, triggering a 180-day compliance period [N2][S2].
• On July 14, 2026, Nasdaq granted the company an additional 180-day extension to regain compliance with the minimum bid price requirement [N1][S2].
• The company has not reported any defaults, dividend arrearages, or delinquencies [S1].
• Corporate governance follows Cayman Islands law and Nasdaq requirements, with some exemptions as a controlled company [S1].